riluzole / Generic mfg. - LARVOL DELTA

Riluzole Restores Circuit and Behavioral Function Altered by Allele-Specific Expression-Mediated LINC02449-CPLX1 Dysregulation. (PubMed, Schizophr Bull) - "These results demonstrate that synaptic and behavioral abnormalities caused by ASE-driven lncRNA dysregulation are pharmacologically reversible. Riluzole represents a promising candidate for repurposing in neuropsychiatric disorders characterized by glutamatergic imbalance and frontostriatal circuit dysfunction, and highlights ASE-regulated lncRNAs as actionable therapeutic targets."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Anti-inflammatory treatment confirms rsfMRI and TSPO PET as biomarkers of functional connectivity and neuroinflammation in rat contusion spinal cord injuries. (PubMed, Sci Rep) - "Riluzole, a neuroprotective agent, has demonstrated efficacy in preserving tissue integrity and improving motor function following SCI...Our results demonstrate reductions in rsFC disruption, validating the role of rsFC as biomarkers of SCI severity and progression. The imaging biomarkers can be used to evaluate the responsiveness to treatment and efficacy of novel therapies in preclinical studies."

Journal • Preclinical • CNS Disorders • Inflammation • Musculoskeletal Diseases • Orthopedics

Unrevealing possible mechanism of Riluzole, Salsalate and Nimodipine in Alzheimer's disease: multi-target network pharmacological perspective. (PubMed, Inflammopharmacology) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders

A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB versus Riluzole in participants with Amyotrophic Lateral Sclerosis (clinicaltrialsregister.eu) - P1/2 | N=116 | Recruiting | Sponsor: Oslo University Hospital HF | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions. (PubMed, Front Oncol) - "Corticosteroids, particularly dexamethasone (DEX), are widely used in the supportive management of glioblastoma and grade 4 astrocytoma because of their rapid efficacy in reducing vasogenic cerebral edema and alleviating neurological symptoms...While experimental studies have reported anti-proliferative and anti-migratory effects of DEX in glioma models, accumulating clinical and translational evidence suggests detrimental interactions with radiotherapy (RT) and temozolomide (TMZ), particularly when steroids are administered at higher doses or during RT...Emerging therapeutic strategies, including agents targeting epigenetic regulators, metabolic pathways, or repurposed drugs such as Riluzole, Metformin, Mifepristone, and Chlorpromazine, show promise in mitigating steroid-associated resistance to TMZ. Collectively, these findings emphasize the complex, context-dependent role of corticosteroids in glioblastoma or grade 4 astrocytoma and emphasize the need for optimized..."

Journal • Review • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Riluzole as a dual targeted radiosensitizer for osteosarcoma: Targeting tumor cells and angiogenic vasculature to enhance single high dose radiotherapy efficacy (AACR 2026) - "Additionally, pre-treatment with Riluzole reduced VEGFA levels in OS cells, suggesting its potential anti-angiogenic activity. In the long term, our objective is to translate these laboratory discoveries into pre-clinical and clinical studies, potentially offering a novel therapeutic approach of radiation therapy for OS patients."

Clinical • Tumor cell • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • PARP1 • SLC7A11

Riluzole for Motor Recovery in Patients With Traumatic Spinal Cord Injury (SCCM 2026) - "Riluzole administration in patients with SCI was not associated with statistically or clinically significant improvements in motor recovery."

Clinical • CNS Disorders • Hypotension • Orthopedics

RILUZOLE-ASSOCIATED BRUGADA PATTERN WITH SYNCOPE: A NOVEL CASE OF DRUG-INDUCED PHENOCOPY (ACC 2026) - "Riluzole may unmask a Brugada phenotype with syncope. Awareness of this potential trigger can prevent misattribution to vasovagal syncope and prompt guideline-based evaluation."

Clinical • Cardiovascular • Genetic Disorders

Exploratory Post Hoc Analysis of Neutrophil-to-lymphocyte Ratio as a Novel Response Biomarker for Edaravone Oral Suspension-treated Patients with Amyotrophic Lateral Sclerosis vs Untreated Propensity Score-matched PRO-ACT Historical Placebo Controls (AAN 2026) - P3 | "Objective: Assess Neutrophil-to-Lymphocyte Ratio (NLR) response to edaravone oral suspension treatment in patients with amyotrophic lateral sclerosis (ALS) and whether baseline NLR may predict NLR response vs propensity score-matched Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) placebo controls.Background: The US Food and Drug Administration (FDA) approved an on/off dosing regimen of Radicava ORS® (edaravone) oral suspension for patients with ALS...MT-1186-A01/A02/A03/A04 patients were propensity score-matched 1:1 on 11 baseline variables with historical, PRO-ACT controls (patients given placebo may have received riluzole)... Edaravone oral suspension treatment in MT-1186 studies vs PRO-ACT controls supports the possible role of NLR as a novel ALS prognostic biomarker. These analyses were non-randomized comparisons, and there was a potential time bias between matched groups. Further studies are needed to validate NLR as a prognostic biomarker..."

Biomarker • Clinical • Retrospective data • Amyotrophic Lateral Sclerosis • CNS Disorders

Regulation of Autophagy and Metabolism in Hepatocellular Carcinoma: Involvement of Wnt-β-Catenin Pathway. (PubMed, J Cell Mol Med) - "Riluzole disrupts mitochondrial homeostasis by increasing Bax/Bcl-2 ratio, resulting in a drop of mitochondrial membrane potential. In conclusion, riluzole inhibits HCC growth by regulating glucose and glutamine metabolism and inducing autophagic cell death, thereby highlighting its therapeutic potential for HCC treatment."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • ATG5 • BAX • BCL2 • BECN1 • CCND1 • DNMT1 • LDHA • MYC • PKM • SLC2A1 • SLC2A3 • WNT3A

Pharmacotherapy in the acute phase of secondary spinal cord injury: an updated narrative review. (PubMed, Eur J Med Res) - "Similar results were observed with levetiracetam...Riluzole demonstrated higher and better motor and sensory scores and improved impairment grading...Hepatocyte growth factor (HGF) aids in motor function recovery, particularly in the lower limbs. Future progress in the pharmacological management of the acute phase of secondary spinal cord injury will depend on methodologically robust clinical trials with improved patient stratification, standardised therapeutic windows, and clinically meaningful outcome measures."

Journal • Review • Cardiovascular • CNS Disorders • Infectious Disease • Inflammation • Orthopedics • HGF

How to improve statistical power in a trial with SCA2 patients using natural history data. (PubMed, Trials) - "Applying the PPCT, prognostic covariate adjustment, or H-AIPW methods helps reduce confidence intervals, enhance statistical power, or decrease the required sample size for the trial by leveraging information from external data. Although the ATRIL's trial conclusion on riluzole remains unchanged, these methods could have enabled the selection of fewer patients, which is crucial for rare neurodegenerative diseases."

Clinical • Journal • Ataxia • CNS Disorders • Movement Disorders

Historical Initiatives Characterizing French – Japanese Treatment Development for 19th Century Bubonic Plague (BP) and 20th-21st Century Amyotrophic Lateral Sclerosis (ALS) (AAN 2026) - "Rhone-Poulenc-Rorer (RPR), a French pharmaceutical company that discovered chlorpromazine began developing riluzole for epilepsy and stroke in the late 1980s. 19th century strategies to internationally project Pasteur Institute research and vaccine expansion were followed by commercial development to support the vaccine infrastructure. 20th century commercial development of riluzole led to dispersal in Japan of ALS clinical trial networks that supported development of edaravone/mecobalamin."

Amyotrophic Lateral Sclerosis • Cardiovascular • CNS Disorders • Epilepsy

Two Cases of Chorea-acanthocytosis (VPS13A Disease) (AAN 2026) - "He experienced severe leg pain, which improved alongside psychosis and dyskinesias with low-dose aripiprazole...Treatment with riluzole helped stabilize symptoms six years after onset... These cases reinforce the clinical heterogeneity of chorea-acanthocytosis, which can mimic Huntington disease. While no cure exists, early recognition can guide supportive care and counseling. The pathophysiology involves impaired protein trafficking due to chorein deficiency, highlighting potential therapeutic targets."

Clinical • Amyotrophic Lateral Sclerosis • Cardiovascular • CNS Disorders • Dystonia • Epilepsy • Gastrointestinal Disorder • Genetic Disorders • Huntington's Disease • Movement Disorders • Parkinson's Disease • Peripheral Neuropathic Pain

Improving Community Physical and Occupational Therapist Comfort in ALS Care: A Pilot Educational Intervention (AAN 2026) - "Objective: To assess the comfort and decision-making confidence of community physical and occupational therapists (PT/OT) in providing evidence-based care to individuals with amyotrophic lateral sclerosis (pALS).Background: While riluzole and edaravone are approved for disease modification in ALS, multidisciplinary supportive care remains the cornerstone of management... This pilot educational intervention suggests that targeted outreach can improve provider comfort and confidence in managing ALS-related rehabilitation. Ongoing educational efforts and development of evidence-based PT/OT guidelines are needed to better support providers caring for this population."

Amyotrophic Lateral Sclerosis • CNS Disorders

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: University of California, Irvine

New P2 trial • Breast Cancer • Cognitive Disorders • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Liver Cancer • Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor

RILUSCI: Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Assistance Publique Hopitaux De Marseille | Initiation date: Dec 2016 ➔ Nov 2017 | Trial primary completion date: Dec 2019 ➔ Nov 2020

Trial initiation date • Trial primary completion date • CNS Disorders • Movement Disorders • Orthopedics

RILUSCI: Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Assistance Publique Hopitaux De Marseille

New P2 trial • CNS Disorders • Movement Disorders • Orthopedics • Rare Diseases

RILUSCI: Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Assistance Publique Hopitaux De Marseille | Unknown status ➔ Recruiting | Trial completion date: May 2021 ➔ Dec 2023 | Trial primary completion date: Nov 2020 ➔ Nov 2023

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Orthopedics • Rare Diseases

AB23005: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) (clinicaltrialsregister.eu) - P2/3 | N=135 | Not yet recruiting | Sponsor: Ab Science

New P2/3 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • Neutropenia

NADALS-001-ALS: Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1/2 | N=90 | Recruiting | Sponsor: Biogipuzkoa Health Research Institute

New P1/2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

AO Spine Clinical Practice Recommendations for Adjunctive Medical Therapies in Acute Traumatic Spinal Cord Injury: Contemporary Concepts. (PubMed, Global Spine J) - "Article 3: Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS)...The development of emerging medical and non-surgical treatments to augment timely and adequate decompression requires critical consideration as new data becomes available. While some topics do not have the scientific backing to be able to make a recommendation at this time, they point towards areas of future study.[Formula: see text]."

Journal • CNS Disorders • Orthopedics

C9orf72-derived dipeptide repeat proteins poly-PR disrupt membrane excitability and synaptic function in cortical neurons. (PubMed, Neurobiol Dis) - "The increased membrane excitability can be restored by Nav channel inhibitor riluzole and Kv7 channel activator retigabine. Our results suggest a rescuable ion channel-mediated hyperexcitability induced by poly-PR expression in cortical neurons, providing a foundation for developing targeted therapies for C9orf72 ALS."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders

Four decades of ALS care: a retrospective study of epidemiology, clinical course and changes in management. (PubMed, Amyotroph Lateral Scler Frontotemporal Degener) - "Use of riluzole, percutaneous endoscopic gastrostomy, and noninvasive ventilation (NIV) increased over the study period, whereas median survival remained stable. Emergency initiation of ventilation occurred in 25% (NIV n = 41/167) and 89% (invasive ventilation n = 16/18) of cases in which these treatment modalities were used. This comprehensive regional study reveals a rising incidence of ALS in Trøndelag, with increased adoption of supportive interventions over time."

Journal • Retrospective data • Amyotrophic Lateral Sclerosis • CNS Disorders

Value of Clinical Evidence and Health Economics and Outcomes Research (HEOR) Studies. (PubMed, Muscle Nerve) - "The field of amyotrophic lateral sclerosis offers a compelling example of how clinical evidence derived from global registries and clinical studies has advanced understanding of disease epidemiology, treatment patterns, and the effectiveness of therapies, including riluzole and edaravone. Consequently, this review and the associated supplementary articles are meant to serve as a primer to inform clinicians of the potential contribution of clinical evidence to HEOR studies."

HEOR • Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders